Bayer Net Up 158% To Rs 10.33 Crore

Image
BSCAL
Last Updated : Mar 20 1997 | 12:00 AM IST

Bayer (India) posted a 158 per cent rise on an annualised basis in its net profit to touch Rs 10.33 crore for the year ended December 31, 1996. Sales rose 14.8 per cent on an annualised basis to touch Rs 456.95 crore. Gross profits went up by 21.7 per cent while operating profit recorded an increase of 16.35 per cent. EPS rose to Rs 56.47 from Rs 24.66 last year. Bayer has declared a 25 per cent dividend.

It has made a provision for tax on dividend of Rs 0.4 crore for the first time in view of the tax to be paid on the paid-out profits. It's operating margin also improved from 11.83 per cent to 11.99 per cent.

On an annualised basis, net profit went up from Rs 3 crore to Rs 10.33 crore for 1996. Operating profits rose from Rs 47.10 crore to Rs 54.81 crore. Total income recorded a 14.66 per cent climb from Rs 404.91 crore last year to Rs 464.28 crore. Total expenditure other than interest and depreciation moved up by 14.44 per cent from Rs 357.79 crore to Rs 409.47 crore.

The major contribution to the turnover comes from the agrochemicals division followed by the rubber and the healthcare business. New introductions in agrochemicals included bilfen, a synthetic pyrethroid and dithane M-45, a protectant fungicide. Export of metasystox, a synthetic insecticide, and methyl parathion, a broad spectrum contact insecticide, improved during the year.

Successful launch of baycip (ciprofloxacin) and other formulations like adalat oros, an anti-hypertensive drug, resochin DS, an anti-malarial drug, and Baycort, a dermatitis steroid gave the pharma business a boost.

In the consumer care business, Baygon oilspray recorded a volume growth after a few years of stagnation while Baygon Power continued to be the largest selling variant of aerosol insecticide. Autan, a mosquito repellent was also launched during the year.

On the animal health front, Solfac which is a broad spectrum pyrethroid, made a significant contribution to sales. Bayer will launch Asuntol and Kiltix for treating ticks and fleas, Droncit for tapeworm control and Baytril, an anti infective during '97.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 20 1997 | 12:00 AM IST

Next Story